Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Clin Cancer Res. 2020 Mar 24;26(13):3431–3442. doi: 10.1158/1078-0432.CCR-19-1627

Figure 4. Phenotyping of tumor-associated immune cell populations after treatment in JH716 and KLN205 mouse models.

Figure 4.

A. Therapy regimen and flow cytometry analysis time points (PO, per os, QD, once a day, IP, intraperitoneal). Mice were subcutaneously inoculated with JH716 (3×106) and KLN205 (0.5×106) cells and treated with vehicle, AZD1775 (20mg/kg), anti-PD-1(200μg), or combination therapy for 14 and 9 days, respectively. B-F. Quantification by flow cytometry of (B) CD8+ T cells, (C) Natural killer cells (NK), (D) Ki67+ proliferating NK cells, (E) CD11b+ myeloid cells, (F) Tumor associated-neutrophils (TANs; CD11b+/MHCII-/Ly6G+/Ly6Clo), (G) Tumor-associated macrophages (TAM; CD11b+/MHCII+/F4/80+/Ly6C-), (H) Tumor-associated monocytes (CD11b+/MHCII+/F4/80-/Ly6C+), (I) Tumor-associated dendritic cells (CD11b+/MHCII+/F4/80-/Ly6C-/CD11c+), in CD45+ TILs from dissociated JH716 tumors. J-Q. Flow cytometry analysis of dissociated KLN205 tumors. Each data point represents one mouse (n=4–5 mice per group). P values were determined by one-way ANOVA analyses. Data are shown as mean ±SEM.